Open Rank Faculty Position-Type 1 Diabetes Immunology

Mayo Career Site UK; Rochester (MN); On-site; USD 140,000 - 200,000; Full time

Job summary

Mayo Clinic in Rochester, Minnesota, invites applications for an open‑rank tenure‑track faculty position dedicated to advancing understanding of autoimmunity in Type 1 diabetes and developing novel immunomodulatory strategies for therapy.

The role emphasizes translational immunology, stem cell biology, and transplantation research, with opportunities to collaborate across clinical and scientific teams to accelerate immune protection and disease modification in islet biology.

Qualifications

• Open-rank tenure-track faculty position focused on autoimmunity in Type 1 diabetes.
• Development of immunomodulatory or disease-modifying therapies is encouraged.
• Experience bridging basic immunology, translational immunology, and stem cell biology is desired.
• Collaborative work with clinical colleagues is highly valued.

Job description

Mayo Clinic announces an open-rank tenure-track faculty recruitment dedicated to advancing understanding and developing treatment strategies for autoimmunity in Type 1 diabetes. The position emphasizes the development of novel immunomodulatory or disease-modifying therapeutic approaches, as well as innovative strategies for immune protection and evasion in stem cell-derived islet cells for the treatment of Type 1 diabetes. This role provides a unique opportunity to contribute at the intersection of islet autoimmunity, translational immunology, islet cell biology, transplantation research, and stem cell biology. Mayo Clinic, ranked first in Diabetes and Endocrinology patient care, seeks candidates who demonstrate excellence in collaborative environments and possess a strong record of partnership with clinical colleagues.

Preferred Research Focus and Expertise

• Mechanisms driving the autoimmune process in Type 1 diabetes
• Establishment of immune tolerance in Type 1 diabetes
• Disease-modifying therapies in Type 1 diabetes
• Modelling autoimmunity and human islet destruction in Type 1 diabetes
• Immune modulation of stem cell-derived islet cells for transplantation
• Immune-islet crosstalk during pathogenesis and progression of Type 1 diabetes

Highlights of Mayo Clinic Research Enterprise

• Over 5,000 research personnel, including 321 faculty level research investigators and 948 physicians who are actively involved in research.
• 11,220 peer-reviewed papers were published in 2024.
• Investments in research each year result in hundreds of new clinical trials. In 2024, the institution received over $753 million in extramural research awards supplemented with over $517 million of institutional support.
• Nearly 10,000 active studies involving human participants in progress. More than 5,900 research grants and contracts.
• State-of-the art laboratories and shared resource facilities, including those for microscopy and imaging, cell and molecular biology, animal models, production of iPS cells and clinical grade MSCs, biomedical engineering and mathematics, materials testing, a Medical Genomics Facility, a Mouse Modeling Facility, Molecular and Microscopic Core Facilities, and unique Human Disease Tissue Banks.
• Over 420,000 square feet of research laboratory space includes several robotic freezers capable of storing 3.5 million DNA samples.
• Mayo Clinic supports innovation and has a wealth of resources available – including an integrated health record and collaboration with top specialists.